Hatch Questions FDA Motive, Process In Proposed Vinpocetine Ban
This article was originally published in The Rose Sheet
Executive Summary
Hatch, primary author of the legislation Congress passed in 1994 as FDA's framework for regulating the supplement industry, notes in a letter that FDA did not question vinpocetine's safety in evaluations of five NDI notifications.
You may also be interested in...
Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards
Amarin's recent fair trade complaint targetting purified EPA dietary supplements and formulations also raises broader questions about using synthetic dietary ingredients in consumer supplements and the extent to which a substance’s identification in an IND precludes subsequent use as a dietary ingredient.
Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards
Amarin's recent fair trade complaint targetting purified EPA dietary supplements and formulations also raises broader questions about using synthetic dietary ingredients in consumer supplements and the extent to which a substance’s identification in an IND precludes subsequent use as a dietary ingredient.
Omega-3 Drug Firm’s Trade Complaint Questions US Dietary Ingredient Standards
Amarin targets purified EPA dietary supplements or formulations containing primarily EPA in ethyl ester or re-esterified form and raises general questions about using synthetic dietary ingredients in supplements and about the extent to which a substance’s previous identification as an IND candidate precludes its subsequent use as a dietary ingredient.